Full text is available at the source.
The XBB.1.5 COVID-19 vaccine elicits a durable antibody response to ancestral and XBB.1.5 SARS-CoV-2 spike proteins
The XBB.1.5 COVID-19 vaccine produces lasting antibodies against original and XBB.1.5 coronavirus spike proteins
AI simplified
Abstract
The XBB.1.5 COVID-19 vaccine induced durable antibody responses with half-lives of 703 days for WA1 and 531 days for XBB.1.5 IgG spike protein binding antibodies.
- A single dose of the XBB.1.5 mRNA vaccine increased the magnitude and breadth of neutralizing antibodies against ancestral and variant SARS-CoV-2 strains.
- IgG1 and IgG4 binding antibodies against the XBB.1.5 spike protein were significantly higher than those against the WA1 spike protein after vaccination.
- High cross-reactivity of antibodies against both WA1 and XBB.1.5 strains was observed and remained durable over time.
- Six months post-vaccination, neutralizing antibodies showed reduced effectiveness against circulating Omicron variants KP.2 and KP.3 compared to XBB.1.5.
- Findings suggest that while the XBB.1.5 vaccine promotes stronger and longer-lasting antibody responses, emerging variants may still evade these defenses.
AI simplified